Systemic Inflammatory Response Induces Multi-Organ Damage After Cardiac Arrest Through IL-17 Pathway in Animal Models
By
Yang Yan
Taiwei Chen
Ancai Yuan
Na Geng
Fang Wan
Peiliang Fang
Zhiqing Qiao
Zhaoling Wei
Jun Pu
April 29, 2026
Clinical Scorecard: Systemic Inflammatory Response Induces Multi-Organ Damage After Cardiac Arrest Through IL-17 Pathway in Animal Models
At a Glance
Category Detail
Condition Post-cardiac arrest syndrome (PCAS) Key Mechanisms IL-17 signaling pathway and systemic inflammation Target Population Patients experiencing cardiac arrest, particularly post-myocardial infarction Care Setting Emergency and critical care settings
Key Highlights
IL-17A is a critical cytokine driving systemic inflammation after cardiac arrest. Early inhibition of IL-17A improves myocardial function and reduces brain injury. Elevated plasma IL-17A levels are observed in patients post-cardiac arrest. Targeting IL-17A may offer a therapeutic strategy for multi-organ injury post-cardiac arrest. PCAS is characterized by myocardial dysfunction, brain injury, and multi-organ dysfunction. Guideline-Based Recommendations
Diagnosis
Assess for myocardial dysfunction and brain injury following cardiac arrest. Monitor plasma IL-17A levels as a potential biomarker for systemic inflammation. Management
Consider early pharmacological inhibition of IL-17A in post-cardiac arrest patients. Monitoring & Follow-up
Regularly evaluate cardiac and neurological function in resuscitated patients. Risks
Persistent systemic inflammation may lead to prolonged organ dysfunction. Patient & Prescribing Data
Survivors of sudden cardiac arrest due to myocardial infarction.
Secukinumab, an IL-17A inhibitor, shows promise in improving outcomes in animal models.
Clinical Best Practices
Implement strategies to monitor and manage systemic inflammation in post-cardiac arrest patients. Utilize IL-17A levels as a potential target for therapeutic intervention. References
